Pricing
Prices are indicative MRP and may vary by pharmacy. Trend compares against the last recorded price.
All price changes →Save on this medicine
Same active ingredient — pay up to 17% less
These brands contain the same active ingredient (Ledipasvir + Sofosbuvir). Strength and form may differ — confirm substitution with your doctor or pharmacist before switching.
Indications & Uses
Ledipasvir + Sofosbuvir is used to treat chronic hepatitis C (CHC) caused by genotype 1 infection in adults.
Dosage Reference
Reference Information Only
Dosages shown are general references from official sources. Always consult your doctor or pharmacist for personalized dosing.
Adults:
Recommended dosage: one tablet (90 mg of Ledipasvir and 400 mg of Sofosbuvir) taken by mouth once daily, with or without food. Recommended treatment duration: 12 weeks for treatment-naive patients with or without cirrhosis, 12 weeks for treatment-experienced patients without cirrhosis, and 24 weeks for treatment-experienced patients with cirrhosis. No dosage recommendation can be made for patients with severe renal impairment or end-stage renal disease.
Side Effects
Fatigue, headache, nausea, diarrhoea and insomnia are the most commonly reported side effects with this tablet, each seen in 10% or more of patients (across all severity grades) taking it for 8, 12, or 24 weeks.
Cautions & Contraindications
Warnings & Precautions
Bradycardia with amiodarone coadministration: Patients taking amiodarone may experience serious symptomatic bradycardia, particularly if they are also on beta-blockers or have underlying cardiac conditions and/or advanced liver disease. Taking amiodarone together with this tablet is not recommended. For patients who have no other viable treatment option, cardiac monitoring is advised. Using this medicine with other drugs containing sofosbuvir is also not recommended.
Contraindications
This combination should not be used in patients who are known to be hypersensitive to ledipasvir, sofosbuvir, or any other ingredient in the product.